UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000024677
Receipt number R000028391
Scientific Title Safety of indocyanine green lymphography for evaluation of lymphedema
Date of disclosure of the study information 2016/11/02
Last modified on 2018/06/30 08:58:43

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Safety of indocyanine green lymphography for evaluation of lymphedema

Acronym

Indocyanine green lymphography for lymphedema

Scientific Title

Safety of indocyanine green lymphography for evaluation of lymphedema

Scientific Title:Acronym

Indocyanine green lymphography for lymphedema

Region

Japan


Condition

Condition

lymphedema

Classification by specialty

Plastic surgery

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Indocyanine green lymphography (ICG)is applied to clinical widely as a liver function test.These days, ICG is performed for evaluation of lymphedema as a preoperative examination.However, the side effects of ICG are not examined. Then, we perform ICG for lyphedema under medical treatment insurance adaptation outside (patient own expense) and evaluated the safety. Specifically, we carry out observation of whethe the general side effects (shock, nausea, blood vessel pain, fever)of ICG occur.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Check whether there are side effects (shock, nausea, blood vessel pain, fever)

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Diagnosis

Type of intervention

Medicine

Interventions/Control_1

We carry out local injection of ICG at dorsum of foot and the inside of foot joint intra- or subcutaneously. We trace the flow of ICG with an infrared observation camera. We carry out observation of whether side effects (shock, nausea, blood vessel pain, fever)happen.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

The person by whom lymphedema continued three months or more and written consent was got.

Key exclusion criteria

Those who have the past of hypersensitivity to iodine. Those who are judged that experimental participation is difficul by moral condition. A pregnant woman, a nursing mother. Moreover, those possible of pregnancy. The person to whom the doctor judged participation of the final examination to be unsuitable.

Target sample size

10


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kazuhiro Toriyama

Organization

Nagoya City University Hospital

Division name

Plastic and reconstructive surgery

Zip code


Address

1-Kawasumi, MIzuho-cho, Mizuho-ku, Nagoya, Japan

TEL

052-858-7514

Email

toriyama@med.nagoya-cu.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Takahumi Uchibori

Organization

Nagoya City University Hospital

Division name

Plastic and reconstructive surgery

Zip code


Address

1-Kawasumi, MIzuho-cho, Mizuho-ku, Nagoya, Japan

TEL

052-858-7514

Homepage URL


Email

uchibori83@gmail.com


Sponsor or person

Institute

Nagoya city university hospital

Institute

Department

Personal name



Funding Source

Organization

Nagoya City University Hospital

Organization

Division

Category of Funding Organization

Local Government

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 11 Month 02 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2016 Year 10 Month 25 Day

Date of IRB


Anticipated trial start date

2016 Year 11 Month 11 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 11 Month 02 Day

Last modified on

2018 Year 06 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028391


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name